Chondroitin sulfate

Overview

Chondroitin sulfate is a glycosaminoglycan considered as a symptomatic slow-acting drug for osteoarthritis (SYSADOA). The SYSADOA status suggested a pain relief and increased joint mobility after a relative long regular administration, as well as a long-lasting effect after the end of the treatment. Chondroitin sulfate is composed of alternating 1,3-N-acetyl-β-d-galactosamine and 1,4-β-d-glucuronic acid units which bear 4-O- and/or 6-O-sulfations at the N-acetylgalactosamine units disposed of in specific patterns. Depending on the predominating disaccharide unit, it will present different biological activities. Chondroitin sulfate is sold as an OTC dietary supplement in North America and it is a prescription drug under the EMA in Europe.

Indication

Chondroitin sulfate, used with glucosamine, is indicated to alleviate pain and inflammation from primary osteoarthritis. This supplement is reported to improve joint function and slow disease progression. Osteoarthritis is characterized by progressive structural and metabolic changes in joint tissues, mainly cartilage degradation, subchondral bone sclerosis and inflammation of synovial membrane. Studies have proposed the potential use of chondroitin sulfate as a nutraceutical in dietary supplements.

Associated Conditions

Back pain
Muscle Strain
Myalgia
Osteoarthritis (OA)
Sprains
Articular inflammation

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
Study on Structum® in Adult Patients With Osteoarthritis (TRUST)	2024/10/02	NCT06623773	N/A	Completed	Pierre Fabre Medicament
Phase I Clinical Study of Chondroitin Sulfate for Treatment of NEC	2024/08/09	NCT06547424	Phase 1	Not yet recruiting	Indiana University
Condrosulf vs Celebrex vs Placebo in the Treatment of Knee OA	2014/03/06	NCT02079727	Phase 3	Completed	IBSA Institut Biochimique SA
Study of the Effect of Chondroitin Sulfate on Structural Changes in Knee Osteoarthritis Patients Assessed by MRI	2011/05/16	NCT01354145	Phase 3	Completed	Bioiberica
Chondroitin Sulfate for Crohn's Disease	2010/11/22	NCT01245088	Phase 1	Withdrawn	University Hospitals Cleveland Medical Center
Chondroitin Sulphate Treatment Efficacy in Rhizarthrosis.	2010/11/03	NCT01233739	Phase 4	UNKNOWN	Juan A. Arnaiz
Glucosamine/Chondroitin Arthritis Intervention Trial (GAIT)	2002/04/08	NCT00032890	Phase 3	Completed	US Department of Veterans Affairs

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
Lifetime Glucosamine Chondroitin Premium Gold Joint Care	297838	Lifetime Pharmaceuticals	Medicine	A	12/20/2017

Health Canada Drug Approvals

Approved Product	Company	DIN	Dosage Form	Strength	Market Date
No Health Canada approvals found for this drug.

CIMA AEMPS Drug Approvals

Approved Product	Company	Registration Number	Pharmaceutical Form	Prescription Type	Status
No CIMA AEMPS (Spain) approvals found for this drug.

Philippines FDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Philippines FDA approvals found for this drug.

Saudi SFDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Saudi SFDA approvals found for this drug.

Malaysia NPRA Drug Approvals

Approved Product	Company	Registration Number	Dosage Form	Strength	Approval Date
No Malaysia NPRA approvals found for this drug.

UK EMC Drug Information

Medicine Name	MA Holder	MA Number	Pharmaceutical Form	Active Ingredient	Authorization Date
No UK EMC drug information found for this drug.

AI-Powered Research

Premium Access